Lineage Cell Therapeutics, Inc.

LCTX

AMEX

Healthcare

Biotechnology

Carlsbad, CA, US70 employeeslineagecell.com

$1.56

-0.03(-1.57%)

Mkt Cap $390M

$0.39

$1.96

52-Week Range

At a Glance

AI-generated

Lineage Cell Therapeutics reported a net loss attributable to Lineage of $63.5 million for FY 2025, a significant increase from an $18.6 million loss in FY 2024.

8-K

Lineage Cell Therapeutics, Inc. reported Q4 and full year 2025 financial results, including Q4 revenues of $6.6 million, net income of $0.9 million or $0.004 per share, and cash of $55.8 million as of December 31, 2025, expected to support operations into Q2 2028. Key highlights include achieving the first milestone under the Roche/Genentech collaboration for RG6501 (OpRegen) and positive 36-month Phase 1/2a study results.

$390M

Market Cap

—

Revenue

—

Net Income

Employees70

Fundamentals

How The Business Makes Money

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Industry Biotechnology

Activity

What Changed Recently

Financial Results

Mar 4, 2026

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)

Other Event

Mar 10, 2026

Other Events. On March 11, 2026, Lineage Cell Therapeutics, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) a prospectus

Peer Companies

Company	Price	Change	Market Cap	P/E
RAPTRAPT Therapeutics, Inc.	$58.01	+0.00%	$959M	-14.8
OMEROmeros Corporation	$10.94	-9.44%	$776M	-5.8
OCGNOcugen, Inc.	$1.78	-0.28%	$585M	-9.7
ADCTADC Therapeutics S.A.	$3.80	+0.03%	$483M	-4.3
FULCFulcrum Therapeutics, Inc...	$8.06	+7.75%	$436M	-5.8
AUTLAutolus Therapeutics plc	$1.42	+2.90%	$378M	-1.7
PRTCPureTech Health plc	$15.51	+3.40%	$377M	7.3
NGNENeurogene Inc.	$21.45	-0.97%	$334M	-4.8

Analyst View

Company Profile

CIK0000876343

ISINUS53566P1093

CUSIP53566P109

Phone442 287 8990

Address2173 Salk Avenue, Carlsbad, CA, 92008, US

SEC EDGAR